Factory Mutual Insurance Co. Raises Position in Danaher Co. (NYSE:DHR)

Factory Mutual Insurance Co. boosted its position in shares of Danaher Co. (NYSE:DHR) by 39.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 206,400 shares of the conglomerate’s stock after buying an additional 58,100 shares during the period. Factory Mutual Insurance Co.’s holdings in Danaher were worth $57,383,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in DHR. Tsfg LLC lifted its holdings in Danaher by 733.3% in the 1st quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. CarsonAllaria Wealth Management Ltd. purchased a new stake in Danaher during the 2nd quarter valued at about $25,000. nVerses Capital LLC purchased a new position in Danaher in the 2nd quarter worth approximately $25,000. Redmont Wealth Advisors LLC acquired a new position in shares of Danaher during the 1st quarter worth approximately $30,000. Finally, Richardson Financial Services Inc. purchased a new stake in shares of Danaher in the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Matthew Mcgrew sold 16,172 shares of the stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total value of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction that occurred on Thursday, July 25th. The shares were sold at an average price of $275.16, for a total transaction of $2,641,536.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at approximately $5,566,486.80. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Matthew Mcgrew sold 16,172 shares of the company’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 39,659 shares of company stock valued at $11,042,433. 11.10% of the stock is owned by corporate insiders.

Danaher Stock Up 1.5 %

NYSE DHR traded up $3.88 on Friday, hitting $270.33. 1,747,177 shares of the stock were exchanged, compared to its average volume of 2,727,044. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The company has a 50-day moving average price of $270.31 and a 200-day moving average price of $259.20. The company has a market cap of $200.23 billion, a PE ratio of 45.82, a PEG ratio of 4.49 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the firm earned $2.05 earnings per share. Danaher’s quarterly revenue was down 2.9% on a year-over-year basis. Sell-side analysts anticipate that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Shareholders of record on Friday, September 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, September 27th. This represents a $1.08 annualized dividend and a yield of 0.40%. Danaher’s dividend payout ratio is currently 18.31%.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DHR. Stifel Nicolaus raised their price objective on shares of Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a research report on Wednesday, July 24th. Stephens started coverage on Danaher in a report on Tuesday, October 1st. They issued an “overweight” rating and a $315.00 price objective on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $300.00 target price on shares of Danaher in a research report on Friday, September 6th. TD Cowen increased their price target on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Seven research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $282.12.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.